Lead Product(s) : Nomegestrol Acetate,Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety Results from Large Real-World Safety Study in Combined Oral Contraception Published
Details : The real world PRO-E2 safety study confirmed that the risk of venous thromboembolism is at least as low with Zoely (NOMAC-E2) as with levonorgestrel-containing combined oral contraceptives. NOMAC-E2 is only monophasic contraceptive pill using body-identi...
Product Name : Zoely
Product Type : Hormone
Upfront Cash : Inapplicable
October 14, 2021
Lead Product(s) : Nomegestrol Acetate,Estradiol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Estradiol,Nomegestrol Acetate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Approved FDF
Sponsor : Theramex
Deal Size : Undisclosed
Deal Type : Acquisition
Theramex Acquires Commercial Rights for Oral Contraceptive Zoely
Details : Theramex currently markets Zoely® in eleven European countries, and this transaction will bring the total number of more than 50 on a global basis. MSD retains rights in the United States and Canada.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Undisclosed
January 22, 2020
Lead Product(s) : Estradiol,Nomegestrol Acetate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Approved FDF
Sponsor : Theramex
Deal Size : Undisclosed
Deal Type : Acquisition
Reset All
